Ironwood cleared to market dual gout therapy in the USA

22 August 2017

USA-based Ironwood Pharmaceuticals (Nasdaq: IRWD) has been handed approval to market its gout therapy Duzallo (allopurinol and lesinurad) in the USA.

The once-daily oral treatment is designed to combat hyperuricemia - high serum uric acid levels in the blood - associated with gout, and is indicated for use in patients who have not responded adequately to treatment with the standard of care, allopurinol.

Duzallo combines allopurinol with the most recent gout treatment, lesinurad, which is marketed by AstraZeneca as Zurampic. The drug was approved by the FDA in late 2015, and in Europe in early 2016. Ironwood acquired exclusive US rights to the product in April of that year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK